Overview
Also known as:
Clinical phenotype terms— hover any for plain English:
FDA & Trial Timeline
1 eventGroupe Francophone des Myelodysplasies — PHASE3
Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
Treatments
1 availableRytelo
RYTELO is indicated for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia requiring 4 or more red blood cell units over…
RYTELO is indicated for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia requiring 4 or more red blood cell units over 8 weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESA)
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to Myelodysplastic syndrome associated with isolated del(5q) chromosome abnormality.
Community
No community posts yet. Be the first to share your experience with Myelodysplastic syndrome associated with isolated del(5q) chromosome abnormality.
Start the conversation →Latest news about Myelodysplastic syndrome associated with isolated del(5q) chromosome abnormality
No recent news articles for Myelodysplastic syndrome associated with isolated del(5q) chromosome abnormality.
Follow this condition to be notified when news becomes available.
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Common questions about Myelodysplastic syndrome associated with isolated del(5q) chromosome abnormality
Are there clinical trials for Myelodysplastic syndrome associated with isolated del(5q) chromosome abnormality?
Yes — 1 recruiting clinical trial is currently listed for Myelodysplastic syndrome associated with isolated del(5q) chromosome abnormality on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.
Which specialists treat Myelodysplastic syndrome associated with isolated del(5q) chromosome abnormality?
14 specialists and care centers treating Myelodysplastic syndrome associated with isolated del(5q) chromosome abnormality are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.
What treatment and support options exist for Myelodysplastic syndrome associated with isolated del(5q) chromosome abnormality?
1 patient support program are currently tracked on UniteRare for Myelodysplastic syndrome associated with isolated del(5q) chromosome abnormality. See the treatments and support programs sections for copay assistance, eligibility, and contact details.